ライフサイエンスコーパス: disease progression

1 surface expression have been associated with disease progression.

2 =3 mm over 5 years were classified as having disease progression.

3 etabolic dynamics during different stages of disease progression.

4 his binding modulates Abeta accumulation and disease progression.

5 ailure in human immunodeficiency virus (HIV) disease progression.

6 termine whether these changes correlate with disease progression.

7 se or physiological malfunction, or tracking disease progression.

8 a new and promising imaging tool to monitor disease progression.

9 city could play a role in determining Chagas disease progression.

10 rmation into patient-specific predictions of disease progression.

11 d interactions (or encounters) can result in disease progression.

12 s on chromatin to regulate genes relevant to disease progression.

13 may be a critical early step in Alzheimer's disease progression.

14 st Sod1 has been shown to substantially slow disease progression.

15 capacity has previously been correlated with disease progression.

16 ntly inhibiting breast cancer initiation and disease progression.

17 unization strategies aimed at preventing HIV disease progression.

18 urrently no effective treatments that modify disease progression.

19 rosis is a critical step for end-stage liver disease progression.

20 d gene transcript levels selectively late in disease progression.

21 f lymphocyte movement in the pancreas during disease progression.

22 rogression-free survival, and survival after disease progression.

23 ents discontinued treatment, 42 (88%) due to disease progression.

24 as a cause for chronic immune activation and disease progression.

25 ence of small fibre neuropathy and to assess disease progression.

26 diomyopathy, providing an early biomarker of disease progression.

27 g them as potential biomarkers for following disease progression.

28 ltration of muscle fibers, but only early in disease progression.

29 e hypothesized that TGR5 might contribute to disease progression.

30 he immune system, setting the pace for later disease progression.

31 microenvironment and at different stages of disease progression.

32 munity species composition was observed with disease progression.

33 ular events throughout the latency period of disease progression.

34 it is useful to predict response and monitor disease progression.

35 Little is known about the mechanisms of disease progression.

36 n, and nine (3%) had fatal events not due to disease progression.

37 an effective prognostic indicator of severe disease progression.

38 cell invasion and is therefore implicated in disease progression.

39 en R (HuR) as a positive regulator of glioma disease progression.

40 what extent weight loss impacts the rate of disease progression.

41 op to further enrich GAG content and promote disease progression.

42 unization strategies aimed at preventing HIV disease progression.

43 tolerated, medication was administered until disease progression.

44 endently associated with elevated hazard for disease progression.

45 complications, such as surgery, and blocking disease progression.

46 rvention should be guided by symptoms and/or disease progression.

47 macrophages, a process that is essential for disease progression.

48 y lung compliance, albeit while accelerating disease progression.

49 erventional clinical trials that aim to slow disease progression.

50 -inflammation and pro-fibrosis pathways with disease progression.

51 (ER) stress, both of which promote metabolic disease progression.

52 ased pERK1/2 levels in patient specimens and disease progression.

53 gomers and slow or prevent neurodegenerative disease progression.

54 91 patients died, including seven because of disease progression.

55 A Markov model was used to forecast NAFLD disease progression.

56 the no atrophy group showed less aggressive disease progression.

57 435/1449 may contribute to the modulation of disease progression.

58 ciency virus (HIV) are at high risk of liver disease progression.

59 s to overcome remyelination failure and halt disease progression.

60 loss and cytotoxicity does not drive kidney disease progression.

61 onset but become functionally impaired upon disease progression.

62 ties of the transmitted virus play a role in disease progression.

63 oss over to receive nivolumab at the time of disease progression.

64 omoting remyelination are pivotal in halting disease progression.

65 d as hallmarks that correlated with clinical disease progression.

66 3 mouse model of MDS, confirming its role in disease progression.

67 rapid mortality in this model through faster disease progression.

68 or both clinical diagnosis and monitoring AD disease progression.

69 rofile of individual cells in the context of disease progression.

70 nt information that aids in the detection of disease progression.

71 explain why infants are more prone to rapid disease progression.

72 ts exhibit innate resistance and suffer from disease progression.

73 athine penicillin G (BPG) therapy to prevent disease progression.

74 ting tumor vasculature, chemoresistance, and disease progression.

75 seases and establish important biomarkers of disease progression.

76 sistent with in vivo T cell expansion during disease progression.

77 neurological diagnosis or more commonly with disease progression.

78 ects of glucocorticoids on milestone-related disease progression across the lifespan and survival in

79 were independently associated with one-year disease progression after adjustment for traditional ris

80 ents with advanced esophageal cancer who had disease progression after chemotherapy.

81 n patients with a sensitizing EGFR mutation, disease progression after first-line epidermal growth fa

82 erentiated inoperable or metastatic NETs and disease progression after first-line treatment.

83 unctioning (one event, likely due to natural disease progression although causality could not be rule

84 major determinant of subtype differences in disease progression among HIV-1 subtypes; furthermore, w

85 ression in melanoma cells is associated with disease progression and a higher number of lymph node me

86 al processes, such as embryonic development, disease progression and aging.

87 drugs during epileptogenesis prevented both disease progression and blood increase in HMGB1 isoforms

88 We show that the effect is associated with disease progression and can be attributed specifically t

89 (CLL) cases, where they are associated with disease progression and chemorefractoriness.

90 irus (HIV), but its long-term effects on HIV disease progression and comorbidities are unknown.

91 table octreotide, PRRT reduced the hazard of disease progression and death by 79%.

92 re also inversely associated with hazards of disease progression and death.

93 d during acute infection predicts subsequent disease progression and drives CD4 decline independently

94 multiple myeloma (MM) and is correlated with disease progression and drug resistance.

95 potential use for monitoring HD mouse model disease progression and evaluating preclinical disease-m

96 ter pylori-infected individuals might affect disease progression and gastric cancer development.

97 colitis have had limited ability to describe disease progression and identify predictors of treatment

98 These might be used to monitor disease progression and identify therapeutic targets for

99 s that the fecal test is the best marker for disease progression and illustrates that Th1/Th2 (IFN-ga

100 LCI is a useful marker to track early disease progression and may serve as a tool to guide the

101 ts in the placebo group; most were caused by disease progression and none were judged to be related t

102 hose interactions provide multiple paths for disease progression and offer potentially untapped mecha

103 aracteristics may be important in predicting disease progression and outcomes.

104 ant disorders, radical interventions to slow disease progression and palliative measures to improve q

105 This may be important in slowing disease progression and provides insight into the protec

106 d interferon therapies effectively help slow disease progression and reduce the risk of cirrhosis, he

107 id leukemia as a driver of tumor initiation, disease progression and relapse.

108 e central nervous system (CNS) to monitor MS disease progression and response to therapies.

109 ptides, which make the dynamic assessment of disease progression and response to treatment possible.

110 er, to be established whether it can monitor disease progression and serve as surrogate endpoint in c

111 HIT1 concentrations were correlated with ALS disease progression and severity but not with the surviv

112 s axis in DKO prostate tumorigenesis, slowed disease progression and significantly extended survival.

113 he association of time of onset of AutD with disease progression and survival in PD.

114 tion were recorded to assess their effect on disease progression and survival.

115 protein TRIB3 as an important factor in APL disease progression and therapy resistance.

116 ate cancer is an important mechanism driving disease progression and therapy resistance.

117 disease classification subtypes that inform disease progression and therapy.

118 atients who stopped treatment for reasons of disease progression and those who received 4 or fewer cy

119 ore, we aimed to generate a novel measure of disease progression and to identify genetic markers asso

120 these findings by enhancing understanding of disease progression and transmission, and thus the impli

121 died in the ceritinib group died because of disease progression and two (13%) died because of an adv

122 eeks of treatment with a 1-week break, until disease progression, and either oral vandetanib 300 mg p

123 ident chronic kidney disease, chronic kidney disease progression, and end-stage renal disease is not

124 298 patients had fatal adverse events due to disease progression, and nine (3%) had fatal events not

125 th different patients' risk factors for HCA, disease progression, and pathology features of tumors.

126 g: heterogeneity, change in phenotype during disease progression, and resistance.

127 ity-adjusted life years (QALYs), total cost, disease progression, and the probability of corneal tran

128 Sensitive outcome measures for disease progression are needed for treatment trials of S

129 ociated capillary bed at different stages of disease progression are not well understood.

130 where distinct and even opposite effects in disease progression are observed depending on the target

131 ome, genetic variations influencing risk and disease progression are poorly understood.

132 tis patients, but the mechanisms involved in disease progression are poorly understood.

133 n synaptic properties over the course of the disease progression as a function of the motor unit type

134 t does not seem to be associated with faster disease progression as measured using SDOCT.

135 ts with open-angle glaucoma (OAG) experience disease progression at different intraocular pressure (I

136 The proportion of participants who had disease progression at month 24 was 58 (28%) of 206 in t

137 antly delayed the onset of epilepsy, blocked disease progression between 2 and 5 months post-status e

138 Therefore, the need for reliable disease progression biomarkers to complement clinical ra

139 For studies of disease progression, BLI showed noticeable lung infectio

140 s prudent in such neoplasms not only to halt disease progression but also to prevent circulatory comp

141 tion, measured by sj/beta-TREC ratio, in HIV disease progression by analyzing a large number of patie

142 al programs associated with the promotion of disease progression by astrocytes.

143 ApN can act as a preventive agent and delay disease progression by reducing muscle inflammation/inju

144 Given their importance in disease progression, characterisation of PSC activation

145 was defined as the time from diagnosis until disease progression (clinical or radiological progressiv

146 ative colitis had an increased risk of liver disease progression compared with patients with Crohn's

147 follow-up, suggesting greater propensity to disease progression compared with pre-PMF.

148 ceived HMT had a significantly lower risk of disease progression compared with those who underwent OB

149 t together delineate a phenotypic roadmap of disease progression culminating in serially transplantab

150 ticipants were patients treated beyond first disease progression, defined as those who received their

151 response, 38%; stable disease [SD] or local disease progression [DP], 13%) versus 33% of high-grade

152 ed midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analo

153 was implemented to identify determinants of disease progression during individuals' first ART interr

154 (N = 272) or nonsquamous (N = 582) NSCLC and disease progression during or after prior platinum-based

155 Of 3323 patients with advanced NSCLC and disease progression following first-line anticancer ther

156 r prostate cancer-related pain at screening, disease progression following first-line docetaxel treat

157 As experimental readouts we measured disease progression for the parasites and expression in

158 Disease progression, frequent changes in symptoms and si

159 inal overexpression in subjects experiencing disease progression, further strengthening the relations

160 We found that 70% of patients with disease progression had either a delayed or absent PD-1+

161 se osteoarthritis and the ability to predict disease progression has been hampered by the lack of bio

162 functions of MMPs and their contributions to disease progression has progressed.

163 patients had significantly increased risk of disease progression (hazard ratio = 1.77, 95% confidence

164 L or more was associated with higher odds of disease progression (hazard ratio, 3.0; P = .04).

165 I provides longitudinal data to characterize disease progression, heterogeneity, and severity in pati

166 me-dependent variables on MVA analysis, both disease progression (HR, 2.15; 95% CI, 1.54 to 3.00) and

167 lls may be a reliable approach for assessing disease progression.IMPORTANCE We report here that the H

168 To determine the rate of disease progression in a longitudinal natural history st

169 ecoy receptor, MYD1-72, profoundly inhibited disease progression in aggressive preclinical models of

170 Many models of disease progression in Alzheimer's disease (AD) have bee

171 Genetic modifiers alter disease progression in both preclinical models and subje

172 ing use of a single, cross-domain measure of disease progression in both studies.

173 nd have been shown to be powerful markers of disease progression in cancer.

174 ing treatment regimen in an attempt to delay disease progression in clear cell renal cell carcinoma.

175 stically significant changes during cervical disease progression in clinical samples.

176 structing the cell cycle of Jurkat cells and disease progression in diabetic retinopathy.

177 din (TSP)-1 promotes macrophage activity and disease progression in dysferlinopathy.

178 gene expression profile at an early stage of disease progression in FVB/N Cd151 (-/-) mice compared t

179 e association between intestinal healing and disease progression in high-risk patients, a treat-to-ta

180 Chronic hypertension, a driving factor of disease progression in human patients, is lacking in mos

181 of HRCT patterns and their relationship with disease progression in idiopathic pulmonary fibrosis.

182 ion may be beneficial to prevent periodontal disease progression in males.

183 glial activation, and measures of subsequent disease progression in multiple sclerosis patients.

184 rrelates with established risks for fibrotic disease progression in NASH, and plasma lumican FSR corr

185 and Mayinga), recent reports suggest slower disease progression in nonhuman primates.

186 The association of overweight/obesity with disease progression in patients with autosomal dominant

187 Disease progression in patients with chronic lymphocytic

188 ements may not be appropriate for monitoring disease progression in patients with idiopathic pulmonar

189 l, and that targeting these factors may halt disease progression in PD patients.

190 current gold standard for measuring clinical disease progression in PSP is the PSP Rating Scale score

191 termine whether cataract surgery accelerates disease progression in retinitis pigmentosa (RP).

192 he underlying pathophysiology of periodontal disease progression in smokers and suggest that focused

193 d synthase (FASN) expression with increasing disease progression in spontaneous pancreatic cancer mou

194 ngitudinally is a reliable way of monitoring disease progression in STGD.

195 pathology early, but exacerbates it late in disease progression in the APPPS1-21 mouse model of AD.

196 et also identified candidate MRs driving the disease progression in the innate immunity pathways.

197 on tumors from (1) 13 patients who developed disease progression in the remnant pancreas following re

198 in low-BMI patients, which may contribute to disease progression in these patients.

199 sures: The spectrum of clinical features and disease progression in unreported and reported patients

200 uorodeoxyglucose (FDG) can monitor monkeypox disease progression in vivo in nonhuman primates (NHPs).

201 Tracking disease progression in vivo is essential for the develop

202 capacity of viruses from acute infection in disease progression in women who seroconverted in the CA

203 tivariable analysis, factors associated with disease progression included use of HDCT as third-line o

204 Disease progression includes composite mortality, hospit

205 [range, 18-90 years]), 306 (58%) experienced disease progression, including 85 (28%) TBP patients and

206 ining at risk for transmission to others and disease progression, including cirrhosis and hepatocellu

207 evaluating dynamic effects that occur during disease progression, incorporating the influence of biot

208 Addition of ECR quartiles to the model for disease progression increased prediction as seen by an i

209 with multiple abnormalities associated with disease progression, interactions between inherited fact

210 partition seasonal variation in Saprolegnia disease progression into a thermal effect and a latent i

211 ive rilotumumab or placebo monotherapy until disease progression, intolerability, withdrawal of conse

212 b 2 mg/kg every 3 weeks for up to 2 years or disease progression, intolerable toxicity, withdrawal of

213 When disease progression is abrupt, however, other coexisting

214 the major structural gene gagIMPORTANCE HIV disease progression is known to differ between individua

215 So far, the contribution of immune cells to disease progression is largely unknown.

216 hages play a role in microbial infection and disease progression is not fully understood.

217 Disease progression is rapid in human immunodeficiency v

218 although antiretroviral therapy can prevent disease progression, it does not cure HIV infection.

219 J mice with TSP-1 knockout mice and assessed disease progression longitudinally with magnetic resonan

220 A liver disease progression Markov model, which used a lifetime

221 Group differences on secondary endpoints of disease progression measuring cognition and function and

222 d outcomes are consistent with slow rates of disease progression (median doubling time: 84 days, 95%

223 Time to all disease progression milestone events was significantly l

224 ation but a lower frequency of treatment for disease progression, mostly for asymptomatic, local, or

225 However, disease progression (n = 71) was more common than grade

226 e known importance of TGF-betas in promoting disease progression, no inhibitors have been approved fo

227 outcome acute myeloid leukaemia evolution or disease progression occurred in seven (12%) of 59 patien

228 dy alone until unacceptable toxic effects or disease progression occurred.

229 red RT of the TP63 gene as an early event in disease progression of both HGPS and RTS.

230 We connect in vivo disease progression of C57BL/6 mice infected with biolum

231 It is concluded that ECR predicts disease progression of CKD patients.

232 manner, but is unlikely a primary driver of disease progression of dysferlinopathy.

233 A classifier is an effective tool to predict disease progression of early-stage MF at the time of dia

234 eins may find application in attenuating the disease progression of familial amyotrophic lateral scle

235 cision-analytic Markov models of the natural disease progression of HCV in HCC patients and DCC patie

236 t, which lead to beta-catenin activation and disease progression of MDS.

237 s associated with increased leukocytosis and disease progression of the patient.

238 y adapted to study the mechanisms underlying disease progression on all mucosal epithelia, including

239 imilar effects were noted for late-stage HIV disease progression on information processing speed (p=0

240 Another patient, who had had evidence of disease progression on MRI, had withdrawn from the study

241 us cell carcinoma of the head and neck after disease progression on or after one previous platinum-ba

242 oints were time from randomisation to second disease progression or death (PFS2),(32) tumour response

243 2 months versus 1.5 months (hazard ratio for disease progression or death, 0.49; 95% CI, 0.39 to 0.61

244 ths vs. 36 months; adjusted hazard ratio for disease progression or death, 0.65; P<0.001).

245 and 59 patients in the LOH low subgroup had disease progression or died.

246 s in arm B continued bevacizumab alone until disease progression or for a maximum of 18 courses.

247 isplatin or carboplatin every 3 weeks, until disease progression or intolerable toxicity.

248 o on day 1 of repeating 21-day cycles, until disease progression or other discontinuation criteria we

249 Disease progression or recurrence may be more closely re

250 Hazard of disease progression or recurrence was significantly incr

251 y because no guidelines exist for monitoring disease progression or response to treatment.

252 and the date of first recurrence, including disease progression or the development of a new primary

253 mab monotherapy 10 mg/kg every 2 weeks until disease progression or toxicity.

254 d then nivolumab 3 mg/kg every 2 weeks until disease progression or unacceptable toxicity while follo

255 chemotherapy (4-6 cycles or until documented disease progression or unacceptable toxicity).

256 psules (2.5 mg/day) for 28-day cycles, until disease progression or unacceptable toxicity.

257 continued as maintenance every 3 weeks until disease progression or unacceptable toxicity.

258 e activity as a potential means of affecting disease progression, our team set out to develop LRRK2 i

259 of patients in 3 cohorts with different HIV disease progression phenotypes.

260 e replication capacity in acute infection on disease progression, potentially driven by interaction o

261 als, but the lack of validated biomarkers of disease progression presents a challenge when developing

262 urvival (OS), progression-free survival, and disease progression rate in patients.

263 in patients with ALS and correlate with the disease progression rate.

264 vent-free survival (with an event defined as disease progression, relapse, death, allergy to rituxima

265 ral phenotypic properties that contribute to disease progression remain unclear.

266 es in the time interval between pathological disease progression/response to therapeutics and change

267 rsion to Alzheimer's disease (AD) and tracks disease progression, signifying its importance in AD.

268 ortant role in disease initiation as well as disease progression such as germ line predisposition, in

269 Rate of structural disease progression, symmetry between eyes, and test-ret

270 odel provides great opportunity for studying disease progression that could lead to new insight for d

271 A central challenge in understanding the disease progression that leads from the HD mutation to m

272 Despite the allowance of crossover after disease progression, the OS benefit was observed in olde

273 hin the hypoxic BM microenvironment promotes disease progression, therapy resistance and relapse.

274 the skeletal muscle capable of reversing the disease progression, thus making it a potential therapeu

275 urnover rate was predictive for the onset of disease progression to AIDS in SIV-infected adult macaqu

276 protocol was amended to allow patients with disease progression to crossover from treatment of physi

277 but nonzero, probability of transition from disease progression to recovery (median 16% per year, 95

278 b (15 mg/kg on day 1) in 21 day cycles until disease progression, unacceptable toxic effects, volunta

279 plus ipilimumab 1 mg/kg every 6 weeks until disease progression, unacceptable toxicities, or withdra

280 nous infusion) every 2 weeks until confirmed disease progression, unacceptable toxicity, or other cri

281 ients received oral everolimus 10 mg/d until disease progression, unacceptable toxicity, or patient r

282 ated pathologies at early and late stages of disease progression, unifying previous work in the field

283 distribution of lipids in liver tissue with disease progression using advanced mass spectrometry ima

284 Changes over time were correlated with disease progression using multivariate regression.

285 However, little is known about disease progression, viral spread, and tissue tropism of

286 e-center, retrospective, longitudinal study, disease progression was assessed by the ALS Functional R

287 Disease progression was confirmed by biopsy for all pati

288 Disease progression was determined using predefined crit

289 visualization of the data in the context of disease progression we were able to identify a number of

290 pulation in North America with an aggressive disease progression, were distinguished from other SOD1

291 ent of GGR was independently associated with disease progression when adjusting for baseline Gender-A

292 the heart, it largely contributes to cardiac disease progression when dysregulated.

293 Seven patients had previously experienced disease progression while being treated with brentuximab

294 Nineteen patients experienced disease progression while receiving ibrutinib, three wer

295 Evaluation Criteria in Solid Tumors-defined disease progression while receiving sunitinib, or unacce

296 ents with RAI-refractory DTC who experienced disease progression while taking prior VEGFR-targeted th

297 re large number of molecules are impacted by disease progression with significant abundance change is

298 ny BRAF-mutated melanoma patients experience disease progression with targeted BRAF inhibitors, we hy

299 tive surveillance (the serial monitoring for disease progression with the intent to cure) appears to

300 measurable lymphadenopathy by CT or MRI and disease progression within 36 months since their last pr